PCSK9 and its modulation

Clinica Chimica Acta

Volumn 440, Issue , 2015, Pages 79-86

  Cui, Chuan Jue ^a   Li, Sha ^a   Li, Jian Jun ^a  

^a FUWAI HOSPITAL   (China)

Author keywords

Dyslipidemia; Low density lipoprotein cholesterol; Proprotein convertase subtilisin kexin type 9; Review

Indexed keywords

ALIROCUMAB; ANTISENSE OLIGONUCLEOTIDE; BERBERINE; CHINESE DRUG; COMPACTIN; ESTROGEN; EVOLOCUMAB; EZETIMIBE; FIBRIC ACID DERIVATIVE; FRUCTOSE; GROWTH HORMONE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN RECEPTOR; MESSENGER RNA; MONOCLONAL ANTIBODY; PITAVASTATIN; PLACEBO; POLYUNSATURATED FATTY ACID; PROPROTEIN CONVERTASE SUBTILISIN KEXIN TYPE 9; ROSUVASTATIN; SERINE PROTEINASE; SMALL INTERFERING RNA; STEROL; THIOCTIC ACID; THYROTROPIN; UNCLASSIFIED DRUG; XUEZHIKANG; AZETIDINE DERIVATIVE; CHOLESTEROL; HERBACEOUS AGENT; PCSK9 PROTEIN, HUMAN;

AEROBIC EXERCISE; AGE; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHRONIC KIDNEY DISEASE; CIRCADIAN RHYTHM; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DIET RESTRICTION; DYSLIPIDEMIA; FAMILIAL HYPERCHOLESTEROLEMIA; GENETIC VARIABILITY; HEPATITIS C; HUMAN; HYPERCHOLESTEROLEMIA; HYPERINSULINEMIA; HYPERTRIGLYCERIDEMIA; INFLAMMATION; INSULIN RESISTANCE; LIPID DIET; LIPOPROTEIN METABOLISM; LIVER REGENERATION; MEDITERRANEAN DIET; NEPHRITIS; NONHUMAN; OBESITY; PERIODONTITIS; PREGNANCY; REVIEW; SEX DIFFERENCE; SINGLE DRUG DOSE; THYROID CANCER; TRANSCRIPTION REGULATION; ANTAGONISTS AND INHIBITORS; DIET; EXERCISE; GENETICS; KIDNEY DISEASE; METABOLISM; MOLECULARLY TARGETED THERAPY; PROCEDURES; RISK FACTOR;

AGE FACTORS; ATHEROSCLEROSIS; AZETIDINES; CHOLESTEROL; CIRCADIAN RHYTHM; DIET; DRUGS, CHINESE HERBAL; EXERCISE; FIBRIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; INSULIN RESISTANCE; KIDNEY DISEASES; LIVER REGENERATION; MOLECULAR TARGETED THERAPY; PROPROTEIN CONVERTASES; RISK FACTORS; SERINE ENDOPEPTIDASES;

EID: 84913570284     PISSN: 00098981     EISSN: 18733492     Source Type: Journal    
DOI: 10.1016/j.cca.2014.10.044     Document Type: Review

References (114)

1. Li J.J. Inflammation in coronary artery diseases. Chin Med J 2011, 124:3568-3575.
2. Li J.J., Yang P., Liu J., et al. Impact of 10mg rosuvastatin daily or alternate-day on lipid profile and inflammatory markers. Clin Chim Acta 2012, 413(1-2):139-142.
3. Seidah N.G., Benjannet S., Wickham L., et al. The secretory proprotein convertase neural apoptosis-regulated convertase 1 (NARC-1): liver regeneration and neuronal differentiation. Proc Natl Acad Sci U S A 2003, 100:928-933.
4. Wu N.Q., Li J.J. PCSK9 gene mutations and low-density lipoprotein cholesterol. Clin Chim Acta 2014, 431:148-153.
5. Guo Y.L., Zhang W., Li J.J. PCSK9 and lipid lowering drugs. Clin Chim Acta 2014, 437C:66-71.
6. Seidah N.G., Awan Z., Chretien M., Mbikay M. PCSK9 a key modulator of cardiovascular health. Circ Res 2014, 114:1022-1036.
7. Benjannet S., Rhainds D., Essalmani R., et al. NARC-1/PCSK9 and its natural mutants: zymogen cleavage and effects on the low density lipoprotein (LDL) receptor and LDL cholesterol. J Biol Chem 2004, 279:48865-48875.
8. Zaid A., Roubstsova A., Essalmani R., et al. Proprotein convertase subtilisin/kexin type 9 (PCSK9): hepatocyte-specific low-density lipoprotein receptor degradation and critical role in mouse liver regeneration. Hepatology 2008, 48:646-654.
9. Chen Y.Q., Troutt J.S., Konrad R.J. PCSK9 is present in human cerebrospinal fluid and is maintained at remarkably constant concentrations throughout the course of the day. Lipids 2014, 49:445-455.
10. Ferri N., Tibolla G., Pirillo A., et al. Proprotein convertase subtilisin kexin type 9 (PCSK9) secreted by cultured smooth muscle cells reduces macrophages LDLR levels. Atherosclerosis 2012, 220:381-386.
11. Cariou B., Le May C., Costet P. Clinical aspects of PCSK9. Atherosclerosis 2011, 216:258-265.
12. Mayer G., Poirier S., Seidah N.G. Annexin A2 is a C-terminal PCSK9-binding protein that regulates endogenous low density lipoprotein receptor levels. J Biol Chem 2008, 283:31791-31801.
13. Benjannet S., Rhainds D., Hamelin J., Nassoury N., Seidah N.G. The proprotein convertase (PC) PCSK9 is inactivated by furin and/or PC5/6A: functional consequences of natural mutations and post-translational modifications. J Biol Chem 2006, 281:30561-30572.
14. Lambert G., Charlton F., Rye K.A., Piper D.E. Molecular basis of PCSK9 function. Atherosclerosis 2009, 203:1-7.
15. Chan D.C. Regulation of proprotein convertase substilisin/kexin type 9: therapeutical perspectives. Atherosclerosis 2011, 217:77-79.
16. Chan D.C., Lambert G., Barrett P.H., Rye K.A., Ooi E.M., Watts G.F. Plasma proprotein convertase subtilisin/kexin type 9: a marker of LDL apolipoprotein B-100 catabolism?. Clin Chem 2009, 55:2049-2052.
17. Cariou B., Ouguerram K., Zaïr Y., et al. PCSK9 dominant negative mutant results in increased LDL catabolic rate and familial hypobetalipoproteinemia. Arterioscler Thromb Vasc Biol 2009, 29:2191-2197.
18. Jeong H.J., Lee H.S., Kim K.S., Kim Y.K., Yoon D., Park S.W. Sterol-dependent regulation of proprotein convertase subtilisin/kexin type 9 expression in sterol-regulatory element binding protein-2. J Lipid Res 2008, 49:399-409.
19. Li H., Dong B., Park S.W., Lee H.S., Chen W., Liu J. Hepatocyte nuclear factor 1 alpha plays a critical role in PCSK9 gene transcription and regulation by the natural hypocholesterolemic compound berberine. J Biol Chem 2009, 284:28885-28895.
20. Li H., Liu J. The novel function of HINFP as a co-activator in sterol-regulated transcription of PCSK9 in HepG2 cells. Biochem J 2012, 443:757-768.
21. Langhi C., Le May C., Kourimate S., et al. Activation of the farnesoid X receptor represses PCSK9 expression in human hepatocytes. FEBS Lett 2008, 582:949-955.
22. Kourimate S., Le May C., Langhi C., et al. Dual mechanisms for the fibrate-mediated repression of proprotein convertase subtilisin/kexin type 9. J Biol Chem 2008, 283:9666-9673.
23. König B., Koch A., Spielmann J., Hilgenfeld C., Stangl G.I., Eder K. Activation of PPAR alpha lowers synthesis and concentration of cholesterol by reduction of nuclear SREBP-2. Biochem Pharmacol 2007, 73:574-585.
24. Duan Y., Chen Y., Hu W., et al. Peroxisome proliferator-activated receptor γ activation by ligands and dephosphorylation induces proprotein convertase subtilisin kexin type 9 and low density lipoprotein receptor expression. J Biol Chem 2012, 287:23667-23677.
25. Cameron J1., Holla Ø.L., Ranheim T., Kulseth M.A., Berge K.E., Leren T.P. Effect of mutations in the PCSK9 gene on the cell surface LDL receptors. Hum Mol Genet 2006, 15(9):1551-1558.
26. Abifadel M., Rabes J.P., Devillers M., et al. Mutations and polymorphisms in the proprotein convertase subtilisin kexin 9 (PCSK9) gene in cholesterol metabolism and disease. Hum Mutat 2009, 30:520-529.
27. Allard D., Amsellem S., Abifadel M., et al. Novel mutations of the PCSK9 gene cause variable phenotype of autosomal dominant hypercholesterolemia. Hum Mutat 2005, 26:497.
28. Mayne J., Dewpura T., Raymond A., et al. Novel loss-of-function PCSK9 variant is associated with low plasma LDL cholesterol in a French-Canadian family and with impaired processing and secretion in cell culture. Clin Chem 2011, 57:1415-1423.
29. Cohen J., Pertsemlidis A., Kotowski I.K., Graham R., Garcia C.K., Hobbs H.H. Low LDL cholesterol in individuals of African descent resulting from frequent nonsense mutations in PCSK9. Nat Genet 2005, 37:161-165.
30. Aung L.H., Yin R.X., Miao L., et al. The proprotein convertase subtilisin/kexin type 9 gene E670G polymorphism and serum lipid levels in the Guangxi Bai Ku Yao and Han populations. Lipids Health Dis 2011, 10:5.
31. Polisecki E., Peter I., Robertson M., et al. Genetic variation at the PCSK9 locus moderately lowers low-density lipoprotein cholesterol levels, but does not significantly lower vascular disease risk in an elderly population. Atherosclerosis 2008, 200:95-101.
32. Kotowski I.K., Pertsemlidis A., Luke A., et al. A spectrum of PCSK9 alleles contributes to plasma levels of low-density lipoprotein cholesterol. Am J Hum Genet 2006, 78:410-422.
33. Abboud S., Karhunen P.J., Lütjohann D., et al. Proprotein convertase subtilisin/kexin type 9 (PCSK9) gene is a risk factor of large-vessel atherosclerosis stroke. PLoS One 2007, 2:e1043.
34. Norata G.D., Garlaschelli K., Grigore L., et al. Effects of PCSK9 variants on common carotid artery intima media thickness and relation to ApoE alleles. Atherosclerosis 2010, 208:177-182.
35. Slimani A., Harira Y., Trabelsi I., et al. Effect of E670G polymorphism in PCSK9 gene on the risk and severity of coronary heart disease and ischemic stroke in a Tunisian cohort. J Mol Neurosci 2014, 53(2):150-157.
36. Le May C., Kourimate S., Langhi C., et al. Proprotein convertase subtilisin/kexin type 9 null mice are protected from postprandial triglyceridemia. Arterioscler Thromb Vasc Biol 2009, 29:684-690.
37. Huang C.C., Fornage M., Lloyd-Jones D.M., Wei G.S., Boerwinkle E., Liu K. Longitudinal association of PCSK9 sequence variations with low-density lipoprotein cholesterol levels: the coronary artery risk development in young adults study. Circ Cardiovasc Genet 2009, 2:354-361.
38. Kostrzewa G., Broda G., Kurjata P., Piotrowski W., Ploski R. Effect of protein convertase subtilisin/kexin type 9 (PCSK9) 46L gene polymorphism on LDL cholesterol concentration in a Polish adult population. Mol Genet Metab 2008, 94:259-262.
39. Scartezini M., Hubbart C., Whittall R.A., Cooper J.A., Neil A.H., Humphries S.E. The PCSK9 gene R46L variant is associated with lower plasma lipid levels and cardiovascular risk in healthy U.K. men. Clin Sci (Lond) 2007, 113:435-441.
40. Sirois F., Gbeha E., Sanni A., Chretien M., Labuda D., Mbikay M. Ethnic differences in the frequency of the cardioprotective C679X PCSK9 mutation in a West African population. Genet Test 2008, 12:377-380.
41. Folsom A.R., Peacock J.M., Boerwinkle E. Atherosclerosis Risk in Communities (ARIC) Study Investigators. Variation in PCSK9, low LDL cholesterol, and risk of peripheral arterial disease. Atherosclerosis 2009, 202:211-215.
42. Baass A., Dubuc G., Tremblay M., et al. Plasma PCSK9 is associated with age, sex, and multiple metabolic markers in a population-based sample of children and adolescents. Clin Chem 2009, 55:1637-1645.
43. Persson L., Cao G., Ståhle L., et al. Circulating proprotein convertase subtilisin kexin type 9 has a diurnal rhythm synchronous with cholesterol synthesis and is reduced by fasting in humans. Arterioscler Thromb Vasc Biol 2010, 30:2666-2672.
44. Gälman C., Matasconi M., Persson L., Parini P., Angelin B., Rudling M. Age-induced hypercholesterolemia in the rat relates to reduced elimination but not increased intestinal absorption of cholesterol. Am J Physiol Endocrinol Metab 2007, 293:E737-E742.
45. Lakoski S.G., Lagace T.A., Cohen J.C., Horton J.D., Hobbs H.H. Genetic and metabolic determinants of plasma PCSK9 levels. J Clin Endocrinol Metab 2009, 94:2537-2543.
46. Cui Q., Ju X., Yang T., et al. Serum PCSK9 is associated with multiple metabolic factors in a large Han Chinese population. Atherosclerosis 2010, 213:632-636.
47. Persson L., Henriksson P., Westerlund E., Hovatta O., Angelin B., Rudling M. Endogenous estrogens lower plasma PCSK9 and LDL cholesterol but not Lp(a) or bile acid synthesis in women. Arterioscler Thromb Vasc Biol 2012, 32:810-814.
48. Peticca P., Raymond A., Gruslin A., et al. Human serum PCSK9 is elevated at parturition in comparison to nonpregnant subjects while serum PCSK9 from umbilical cord blood is lower compared to maternal blood. ISRN Endocrinol 2013, 2013:341632.
49. Kraus W.E., Houmard J.A., Duscha B.D., et al. Effects of the amount and intensity of exercise on plasma lipoproteins. N Engl J Med 2002, 347:1483-1492.
50. Wen S., Jadhav K.S., Williamson D.L., Rideout T.C. Treadmill exercise training modulates hepatic cholesterol metabolism and circulating PCSK9 concentration in high-fat-fed mice. J Lipid 2013, 2013:908048.
51. Ngo Sock E.T., Chapados N.A., Lavoie J.M. LDL receptor and Pcsk9 transcripts are decreased in liver of ovariectomized rats: effects of exercise training. Horm Metab Res 2014, 46:550-555.
52. Calandra S., Tarugi P., Speedy H.E., Dean A.F., Bertolini S., Shoulders C.C. Mechanisms and genetic determinants regulating sterol absorption, circulating LDL levels, and sterol elimination: implications for classification and disease risk. J Lipid Res 2011, 52:1885-1926.
53. Costet P., Cariou B., Lambert G., et al. Hepatic PCSK9 expression is regulated by nutritional status via insulin and sterol regulatory element-binding protein 1c. J Biol Chem 2006, 281:6211-6218.
54. Cariou B., Langhi C., Le Bras M., et al. Plasma PCSK9 concentrations during an oral fat load and after short term high-fat, high-fat high-protein and high-fructose diets. Nutr Metab (Lond) 2013, 10(1):4.
55. Jia Y.J., Liu J., Guo Y.L., Xu R.X., Sun J., Li J.J. Dyslipidemia in rat fed with high-fat diet is not associated with PCSK9-LDL-receptor pathway but ageing. J Geriatr Cardiol 2013, 10:361-368.
56. Richard C., Couture P., Desroches S., et al. Effect of the Mediterranean diet with and without weight loss on surrogate markers of cholesterol homeostasis in men with the metabolic syndrome. Br J Nutr 2012, 107:705-711.
57. Bjermo H., Iggman D., Kullberg J., et al. Effects of n-6 PUFAs compared with SFAs on liver fat, lipoproteins, and inflammation in abdominal obesity: a randomized controlled trial. Am J Clin Nutr 2012, 95:1003-1012.
58. Browning J.D., Horton J.D. Fasting reduces plasma proprotein convertase, subtilisin/kexin type 9 and cholesterol biosynthesis in humans. J Lipid Res 2010, 51:3359-3363.
59. Wu M., Dong B., Cao A., Li H., Liu J. Delineation of molecular pathways that regulate hepatic PCSK9 and LDL receptor expression during fasting in normolipidemic hamsters. Atherosclerosis 2012, 224:401-410.
60. Khovidhunkit W., Kim M.S., Memon R.A., et al. Effects of infection and inflammation on lipid and lipoprotein metabolism: mechanisms and consequences to the host. J Lipid Res 2004, 45:1169-1196.
61. Memon R.A., Staprans I., Noor M., et al. Infection and inflammation induce LDL oxidation in vivo. Arterioscler Thromb Vasc Biol 2000, 20:1536-1542.
62. Clark P.J., Thompson A.J., Vock D.M., et al. Hepatitis C virus selectively perturbs the distal cholesterol synthesis pathway in a genotype-specific manner. Hepatology 2012, 56:49-56.
63. Pileri P., Uematsu Y., Campagnoli S., et al. Binding of hepatitis C virus to CD81. Science 1998, 282:938-941.
64. Scarselli E., Ansuini H., Cerino R., et al. The human scavenger receptor class B type I is a novel candidate receptor for the hepatitis C virus. EMBO J 2002, 21:5017-5025.
65. Syed G.H., Tang H., Khan M., Hassanein T., Liu J., Siddiqui A. Hepatitis C virus stimulates low-density lipoprotein receptor expression to facilitate viral propagation. J Virol 2014, 88:2519-2529.
66. Meertens L., Bertaux C., Cukierman L., et al. The tight junction proteins claudin-1, -6, and -9 are entry cofactors for hepatitis C virus. J Virol 2008, 82:3555-3560.
67. Labonté P., Begley S., Guévin C., et al. PCSK9 impedes hepatitis C virus infection in vitro and modulates liver CD81 expression. Hepatology 2009, 50:17-24.
68. Awan Z., Dubuc G., Faraj M., et al. The effect of insulin on circulating PCSK9 in postmenopausal obese women. Clin Biochem 2014, 47:1033-1039.
69. Niesen M., Bedi M., Lopez D. Diabetes alters LDL receptor and PCSK9 expression in rat liver. Arch Biochem Biophys 2008, 470:111-115.
70. Levy E., Lalonde G., Delvin E., et al. Intestinal and hepatic cholesterol carriers in diabetic Psammomys obesus. Endocrinology 2010, 151:958-970.
71. Dubé E., Ethier-Chiasson M., Lafond J. Modulation of cholesterol transport by insulin-treated gestational diabetes mellitus in human full-term placenta. Biol Reprod 2013, 88:16.
72. Veilleux A., Grenier E., Marceau P., Carpentier A.C., Richard D., Levy E. Intestinal lipid handling: evidence and implication of insulin signaling abnormalities in human obese subjects. Arterioscler Thromb Vasc Biol 2014, 34:644-653.
73. Kwakernaak A.J., Lambert G., Dullaart R.P. Relationship of proprotein convertase subtilisin-kexin type 9 levels with resistin in lean and obese subjects. Clin Biochem 2012, 45:1522-1524.
74. Melone M., Wilsie L., Palyha O., Strack A., Rashid S. Discovery of a new role of human resistin in hepatocyte low-density lipoprotein receptor suppression mediated in part by proprotein convertase subtilisin/kexin type 9. J Am Coll Cardiol 2012, 59:1697-1705.
75. Carrier B., Wen S., Zigouras S., et al. Alpha-lipoic acid reduces LDL-particle number and PCSK9 concentrations in high-fat fed obese Zucker rats. PLoS ONE 2014, 9:e90863.
76. Pearce E.N. Update in lipid alterations in subclinical hypothyroidism. J Clin Endocrinol Metab 2012, 97:326-333.
77. Kwakernaak A.J., Lambert G., Muller Kobold A.C., Dullaart R.P. Adiposity blunts the positive relationship of thyrotropin with proprotein convertase subtilisin-kexin type 9 levels in euthyroid subjects. Thyroid 2013, 23:166-172.
78. Gagnon A., Mahzari M., Lochnan H.A., Sorisky A. Acute TSH stimulation in vivo does not alter serum PCSK9 levels. Thyroid Res 2014, 7:4.
79. Abujrad H., Mayne J., Ruzicka M., et al. Chronic kidney disease on hemodialysis is associated with decreased serum PCSK9 levels. Atherosclerosis 2014, 233:123-129.
80. Vaziri N.D. Dyslipidemia of chronic renal failure: the nature, mechanisms, and potential consequences. Am J Physiol Renal Physiol 2006, 290:F262-F272.
81. Jin K., Park B.S., Kim Y.W., Vaziri N.D. Plasma PCSK9 in nephrotic syndrome and in peritoneal dialysis: a cross-sectional study. Am J Kidney Dis 2014, 63:584-589.
82. Liu S., Vaziri N.D. Role of PCSK9 and IDOL in the pathogenesis of acquired LDL receptor deficiency and hypercholesterolemia in nephrotic syndrome. Nephrol Dial Transplant 2014, 29:538-543.
83. Luo Y., Warren L., Xia D., et al. Function and distribution of circulating human PCSK9 expressed extrahepatically in transgenic mice. J Lipid Res 2009, 50:1581-1588.
84. Seidah N.G., Benjannet S., Wichham L., et al. The sectetory proprotein convertase neural apoptosis-regulated convertase 1 (NARC-1): liver regeneration and neuronal differentiation. Proc Natl Acad Sci USA 2003, 100(3):928-933.
85. Fan J., Watanabe T. Inflammatory reactions in the pathogenesis of atherosclerosis. J Atheroscler Thromb 2003, 10:63-71.
86. Feingold K.R., Moser A.H., Shigenaga J.K., Patzek S.M., Grunfeld C. Inflammation stimulates the expression of PCSK9. Biochem Biophys Res Commun 2008, 374:341-344.
87. Tang Z., Jiang L., Peng J., et al. PCSK9 siRNA suppresses the inflammatory response induced by oxLDL through inhibition of NF-κB activation in THP-1-derived macrophages. Int J Mol Med 2012, 30:931-938.
88. Ranheim T., Mattingsdal M., Lindvall J.M., et al. Genome-wide expression analysis of cells expressing gain of function mutant D374Y-PCSK9. J Cell Physiol 2008, 217:459-467.
89. Wu N.Q., Guo Y.L., Xu R.X., et al. Acute myocardial infarction in an 8-year old male child with homozygous familiar hypercholesterolemia: laboratory findings and response to lipid-lowering drugs. Clin Lab 2013, 59:901-907.
90. Li S., Guo Y.L., Xu R.X., et al. Association of plasma PCSK9 levels with white blood cell count and its subsets in patients with stable coronary artery disease. Atherosclerosis 2014, 234:441-445.
91. Li S., Zhu C.G., Guo Y.L., et al. The relationship between the plasma PCSK9 levels and platelet indices in patients with stable coronary artery disease. J Atheroscler Thromb 2014, 21. [xxx: xxx-xxx, in press].
92. Zhang Y., Zhu C.G., Xu R.X., et al. Relation of circulating PCSK9 concentration to fibrinogen in patients with stable coronary artery disease. J Clin Lipidol 2014, 8(5):494-500.
93. Li S., Guo Y.L., Xu R.X., et al. Plasma PCSK9 levels are associated with the severity of coronary stenosis in patients with atherosclerosis. Int J Cardiol 2014, 174(3):863-864.
94. Miyazawa H., Honda T., Miyauchi S., et al. Increased serum PCSK9 concentrations are associated with periodontal infection but do not correlate with LDL cholesterol concentration. Clin Chim Acta 2012, 413:154-159.
95. Liu J., Guo Y.L., Xu R.X., Li J.J. Rapid effects of different lipid-lowering drugs on PCSK9 in humans. Clin Lipid 2013, 8:519-524.
96. Guo Y.L., Liu J., Xu R.X., Wu N.Q., Jiang L.X., Li J.J. Short-term impact of low-dose atorvastatin on serum proprotein convertase subtilisin/kexin type 9. Clin Drug Investig 2013, 33:877-883.
97. Berge K.E., Ose L., Leren T.P. Missense mutations in the PCSK9 gene are associated with hypocholesterolemia and possibly increased response to statin therapy. Arterioscler Thromb Vasc Biol 2006, 26:1094-1100.
98. Thompson J.F., HydeCL WoodLS, Paciga S.A., et al. Comprehensive whole-genome and candidate gene analysis for response to statin therapy in the treating to new targets (TNT) cohort. Circ Cardiovasc Genet 2009, 2:173-181.
99. Chapman M.J. Fibrates: therapeutic review. Br J Diabetes Vasc Dis 2006, 6:11-18.
100. Catapano A.L., Farnier M., Foody J.M., et al. Combination therapy in dyslipidemia: where are we now?. Atherosclerosis 2014, 237(1):319-335.
101. Ason B., Tep S., Davis H.R., et al. Improved efficacy for ezetimibe and rosuvastatin by attenuating the induction of PCSK9. J Lipid Res 2011, 52:679-687.
102. Davignon J., Dubuc G. Statins and ezetimibe modulate plasma proprotein convertase subtilisin kexin-9 (PCSK9) levels. Trans Am Clin Climatol Assoc 2009, 120:163-173.
103. Zhang Y., Liu J., Li S., Xu R.X., Sun J., Li J.J. Impact of currently prescribed lipid-lowering drugs on plasma PCSK9 concentration: single or in combination study in rats. Lipids Health Dis 2014, 13:35-40.
104. Jia Y.J., Zhang Y., Liu J., Guo Y.L., Xu R.X., Li J.J. Short- and long-term effects of Xuezhikang, an extract of cholestin, on serum proprotein convertase subtilisin/kexin type 9 levels. Chin J Integr Med 2014, 10.1007/s11655-014-1846-y.
105. Cameron J., Ranheim T., Kulseth M.A., Leren T.P., Berge K.E. Berberine decreases PCSK9 expression in HepG2 cells. Atherosclerosis 2008, 201:266.
106. Frank-Kamenetsky M., Grefhorst A., Anderson N.N., et al. Therapeutic RNAi targeting PCSK9 acutely lowers plasma cholesterol in rodents and LDL cholesterol in nonhuman primates. Proc Natl Acad Sci U S A 2008, 105:11915-11920.
107. Cao G.Q., Konrad R.J., Kowala M.C., Wang J. Novel regulators of low-density lipoprotein receptor and circulating LDL-C for the prevention and treatment of coronary artery disease. Coronary artery disease - new insights and novel approaches 2012, 225-242. InTech. A. Squeri (Ed.).
108. Graham M.J., Lemonidis K.M., Whipple C.P., et al. Antisense inhibition of proprotein convertase subtilisin/kexin type 9 reduces serum LDL in hyperlipidemic mice. J Lipid Res 2007, 48:763-767.
109. Gupta N., Fisker N., Asselin M.C., et al. A locked nucleic acid antisense oligonucleotide (LNA) silences PCSK9 and enhances LDLR expression in vitro and in vivo. PLos ONE 2010, 5:e10682.
110. Fruchart J.C. PCSK9: the functional relevance of fenofibrate-stain combination therapy to reduce residual cardiovascular risk. Int J Diab Mellit 2010, 10.1016/j.ijdm.2010.11.001.
111. Raal F.J., Stein E.A., Dufour R., et al. PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial. Lancet 2014, [pii: S0140-6736(14)61399-4], [Epub ahead of print].
112. Raal F.J., Honarpour N., Blom D.J., et al. Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolaemia (TESLA Part B): a randomised, double-blind, placebo-controlled trial. Lancet 2014, [pii: S0140-6736(14)61374-X], [Epub ahead of print].
113. Roth E.M., Taskinen M.R., Ginsberg H.N., et al. Monotherapy with the PCSK9 inhibitor alirocumab versus ezetimibe in patients with hypercholesterolemia: results of a 24week, double-blind, randomized phase 3 trial. Int J Cardiol 2014, 176(1):55-61.
114. Sjouke B., Kusters D.M., Kastelein J.J.P. Familial hypercholesterohemia: present and future management. Curr Cardiol Rep 2011, 13:527-536.